Clinical trials: Diabete Type 1
Diabetes Type I, Diabetes Type II
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
The purpose of this clinical trial is to perform a limited pilot study to determine the safety and feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study.
- Trial name
- NCT02184455
- Testing
- DermGEN
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Dr. Paul F. Gratzer
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Insulin-dependent Diabetes Mellitus, Diabetes Mellitus, Type 1
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy
A multi center, open label, prospective study that will include up to 100 subjects with Type 1 Diabetes treated with Multiple Daily Injections (MDI) of insulin according to a predefined sliding scale plan or carbohydrate ratio…
- Trial name
- NCT04043260
- Testing
- Advisor Pro
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- DreaMed Diabetes
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00406458
- Testing
- SB-509, Normal Saline
- Where
- 15 sites in United States, Mexico
- Volunteers
- 110 people
- Sponsor
- Sangamo Therapeutics
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB
Diabete Mellitus, Medical Device
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
The study was established to collect data and reference measurements in order to establish calibration models for the Prototype 0.3
- Trial name
- NCT03781232
- Testing
- Prototype 0.3
- Where
- 2 sites in Germany
- Volunteers
- 47 people
- Sponsor
- RSP Systems A/S
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
Diabetes, Type I
A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
Purpose: The purpose of the trial is to assess the safety profile of the study treatment and to evaluate its efficacy in terms of improvement in key diabetes management parameters, including insulin requirements and β-cell…
- Trial name
- IMMUNOSTEM (NCT06938334)
- Testing
- Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Altheia Science
Type 1 Diabetes, Type 1 Diabetes (T1D)
Study of IMC-S118AI in Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
- Trial name
- NCT07493122
- Testing
- IMC-S118AI
- Volunteers
- 154 people
- Sponsor
- Immunocore Ltd
Diabetes Type 1
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France.
- Trial name
- EPICAM-G6 (NCT07048795)
- Testing
- No Intervention: Observational Cohort
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- mylife Diabetes Care AG
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT01079325
- Testing
- SB-509, Saline
- Where
- 31 sites in United States
- Volunteers
- 170 people
- Sponsor
- Sangamo Therapeutics
Diabetes Mellitus, Diabetes Mellitus ( Type 1 and Type 2)
PMCF Study of GX-01S CGM in Adults With Diabetes
This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information…
- Trial name
- PROMISE-GX (NCT07802327)
- Testing
- GX-01S Continuous Glucose Monitoring System
- Volunteers
- 100 people
- Sponsor
- MicroTech Medical（Hangzhou）Co.,Ltd.
Quality of Life, Burden, Dependency
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age.
- Trial name
- IMPLIQUE (NCT04939766)
- Testing
- Activation of a closed loop device in an insulin pump device with GCM
- Volunteers
- 250 people
- Sponsor
- VitalAire
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Trial name
- NCT00332826
- Testing
- Technosphere Insulin
- Where
- 78 sites in United States, Argentina and 9 more
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
Diabetes Type 1
InPen User Experience
The purpose of this study is to evaluate the user experience of InPen™ with InPen™ Diabetes Management App and Guardian 4 system in adult patients with type 1 diabetes for the design of a future pivotal study.
- Trial name
- NCT05029271
- Testing
- InPen with Guardian 4 System
- Where
- 3 sites in Sweden
- Volunteers
- 34 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER1 (NCT03371082)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 85 sites in United States, Czechia and 4 more
- Volunteers
- 576 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research